-+ 0.00%
-+ 0.00%
-+ 0.00%

China Grants Breakthrough Therapy Designation to Kelun-Biotech's Sacituzumab Tirumotecan Combo for First-Line PD-L1-Positive NSCLC

路透·01/05/2026 09:28:21

登錄查看新聞詳情